CA2465675C

CA2465675C - Improved particulate compositions for pulmonary delivery

Info

Publication number: CA2465675C
Application number: CA002465675A
Authority: CA
Inventors: Richard P. Batycky; David A. Edwards; Michael M. Lipp
Original assignee: Advanced Inhalation Research Inc
Current assignee: Alkermes Inc
Priority date: 2001-11-20
Filing date: 2002-11-20
Publication date: 2008-06-10
Anticipated expiration: 2022-11-20
Also published as: WO2003043585A2; US7384649B2; AU2002352836B2; AU2002352836A1; DK1455755T3; US7182961B2; ES2415654T3; WO2003043585A3; EP1455755B1; US20070104657A1; EP1455755A2; JP2005511628A; PT1455755E; JP4368198B2; EP1455755A4; CA2465675A1; US20030129139A1

Abstract

This invention concerns an improved particulate composition for delivering a drug to the pulmonary system. Applicants disclose a method of identifying an optimal form of aerodynamically light particles which are highly dispersible.
The particles of the instant invention are made by creating hollow, spherical drug particles (i.e., progenitor particles) that collapse in the process of particle formation, leading to wrinkled, thin-walled drug particles of very low envelope density. Additionally, applicants have found that such particles are especially optimal for inhaled aerosols when the surface area parameter (.SIGMA.) is greater than 2, optimally greater than 3.

Description

]IVIPROVED PARTICULATE COMPOSITIONS FOR PULMONARY DELIVERY
BACKGROUND OF THE INVENTION

Previously Applicants have found that dry powder comprising aerodynamically light particles are suitable for inhalation of drugs into the lungs.
However, there are several problems associated with the aerosol delivery of therapeutic, diagnostic and/or prophylactic agents (hereinafter collectively referred to as drug). For example, electrostatic charge interactions influence the overall efficiency of delivery of dry particles via a Dry Powder hihaler (DPI), since such forces are considered to be significant for attraction and adhesion between the particles themselves as well as between the particles and the device surface.
Additionally, particle size distribution, particle morphology, and moisture content can greatly influence the bulk properties of a dry powder formulation and its performance.

In the case of dry powders comprising aerodynamically light particles, appropriate criteria and tests must be instituted to control parameters considered to be key to ensuring reproducibility of the physicochemical properties of the drug containing particles. Key specification parameters may include color, appearance (visual and microscopic), moisture, melting range, particle size distribution, surface area, form(s), and residual solvents. Specifications for control of particle size distribution and forms (e.g., shape, texture, surface) of the drug containing particles are parameters often used to predict reproducible drug product performance.
The composition of a formulation to be administered via a DPI has a direct effect on the stability of the formulation as well as on the dosing performance of the product. The suitability of a dry powder particulate composition is dependent on its chemical and physical characteristics, which can have direct effect on the performance of the product (e.g., ease of entrainment of the formulation, energy input necessary for dispersion and aerosolization, hygroscopicity of the formulation).
For example, aggregation of dry powder particles may affect the particle size distribution of the emitted drug substance, the homogeneity of the drug substance, the aerodynamic properties of the dry powder particles in the device, and hence the delivered dose.
For DPI's, the target formulation fill weight is important yet it can be deceptive if the particle delivery is variable due to varying levels of aggregation of cohesive particles. Particles produced for inhalation, which are typically small in size (geometric diameter of 1 to 5 m), tend to stick together.
Edwards et al. (U.S. Patent No. 5,985,309)(hereinafter referred to as "Edwards") discloses advantages of aerodynamically light particles for drug delivery to the pulmonary system. Edwards use of larger particles (i.e., mass median diameter of at least about 5 microns) is advantageous since they are able to aerosolize more efficiently than smaller, denser aerosol particles such as those currently used for inhalation therapies.
Thus, there is a need for improved pharmaceutical compositions suitable for pulmonary administration delivered via a dry powder inhaler with improved aerosolization properties and optimized particle-particle interactions. In particular, there is a need for dry powder pharmaceutical compositions which are highly dispersible and which efficiently emit and penetrate into the lungs from a dry powder inhaler.

SUMMARY OF THE INVENTION
This invention concerns an improved particulate composition for delivering a drug to the pulmonary system. A drug may be a therapeutic, diagnostic and/or prophylactic agent. Applicants disclose a method of identifying an optimal form of aerodynamically light particles which are highly dispersible. The particles of the instant invention are made by creating hollow, spherical drug particles (i.e., progenitor particles) that collapse in the process of particle formation, leading to wrinkled, thin-walled drug particles of very low envelope density.
Additionally, Applicants have found that such particles are especially optimal for inhaled aerosols when the surface area parameter (a) is greater than 2, optimally greater than 3.

The invention relates to an improved particulate composition for delivery to the pulmonary system comprising particles having a tap density of less than 0.4 g/cm3 and a median geometric diameter greater than 5 m, and an external surface area greater than about 5 m2/g, preferably greater than about 10 m2/g. In a fiirther embodiment, the particles further comprise a drug. hi another embodiment, the particles further comprise a pharmaceutical excipient. In yet another embodiment, the particles further comprise a dispersibility ratio of between about 1.0 to 1.5 as measured by laser diffraction (RODOS/HELOS system). In a further embodiment, the particles have a skeletal density of at least 1 g/cm3.
In another embodiment, the invention relates to an improved particulate composition for delivery of a drug to the pulmonary system comprising particles having a tap density of less than 0.4 g/cm3 and a geometric diameter greater than 5 m, said particles having a continuous collapsed hollow sphere wall, said wall having a wall thickness less than about 150 nanometers and an external surface area of at least 5 m2/g. In a further embodiment, at least 70% of the particles of the particulate composition have a fine particle fraction of less than 5.6 m.
In another embodiment, the invention relates to a method for maximizing drug delivery to the pulmonary system comprising: a) spray drying a mixture comprising the drug and a pharmaceutically acceptable excipient to form spray dried particles; b) measuring an average wall thickness of the spray dried particles; c) adjusting spray drying conditions to minimize the average wall thickness; d) collecting spray dried particles having minimized average wall thickness; and e) administering spray dried particles having minimized average wall thickness to the respiratory tract of a patient in need of the drug.

BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views.

Figure 1 is an SEM image of a representative formulation i (spherical paper morphology) powder particle.
Figure 2 is an SEM image of a representative formulation ii (crumpled paper morphology) powder particle.
Figure 3 is an SEM image showing the wall thickness of a representative formulation i (spherical morphology) powder particle.
Figure 4 is an SEM image showing the wall thickness of a representative formulation ii (crumpled paper morphology) powder particle.

DEFINITIONS
As used herein, the term "wall thickness" refers to the average thickness of the wall of a particle. For thin walled particles of the invention, wall thickn.ess is on the order of about 50-150 nm, preferably from about 75 to 125 nm, which is about 1 10 of the spherical envelope diameter of the particle. Measurement techniques are known to those skilled in the art and include, but are not limited to, visual observations (e.g., SEM, TEM), or are calculated as a function of spherical envelope diameter, tap density and surface area.
As used herein, the teml "spherical envelope diameter" refers to the diameter of a sphere that completely encompasses a given particle.
As used herein, the term "envelope density" refers to the ratio of the mass of a particle to the sum of the volumes of the solid in each piece and the voids within each piece, that is, within close-fitting imaginary envelopes completely surrounding each piece. In other words, envelope density refers to the ratio of the mass of a particle to the envelope volume of the particle.
As used herein, the terms "contiguous shell surface" or "shell-based particles", used to describe the particles of the instant invention, refers to hollow particles characterized by a single wall with an internal and an external surface (i.e., balloon-like). The wall is typically considered to be a closed and contiguous surface, although some cracks and/or blowholes can occur. Some particles disclosed in the art have walls that are microporous (sponge-like) in nature and have multiple walls on their interiors and have not been formed from a single shell as defined above.

As used herein, the term "external surface area" refers to the surface area on the exterior side of the contiguous shell surface for particles of the invention. The external surface area of shell-based particles with contiguous solid walls can be measured via techniques know to those of skill in the art that include, but are not limited to, Atomic Force Microscopy (AFM) and BET isotherm analysis. For example, crumpled particles of the invention having a geometric diameter of approximately 10 microns, have external surface areas as measured by BET
isotherm analysis of about 12 to about 15 square meters per gram. This is a value of approximately twice the external surface area of a smooth, spherical particle of the same spherical envelope diameter and tap density as the crumpled particle. A
range of external surface area for particles of the invention is from about 5 to about 50 square meters/gram. Preferably, a range of external surface area for particles of the invention is from about 8 to about 25 square meters/gram. More preferably, a range of external surface area for particles of the invention is from about 10 to about 15 square meters/gram.
As used herein, the term "internal surface area" refers to the surface area on the interior side of the contiguous shell surface for particles of the invention. The internal surface area of shell-based particles with contiguous solid walls cannot be measured directly via techniques such as Atomic Force Microscopy (AFM) and BET
isotherm analysis, but can be estimated based on the external particle surface area and particle wall thickness. For cases such as those described here involving shell-based particles with wall thicknesses much less than the particle spherical envelope diameter, the internal surface area will be approximately equal to the external surface area.
As used herein, the term "skeletal density" refers to the ratio of the mass of discrete pieces of solid material to the sum of the volumes of the solid material in the pieces and closed (blind) pores within the pieces. The particles of the instant invention have skeletal densities from about 1 to about 1.3 g/cm3, preferably 1.2 g/cm3, which is equivalent to the dense bulk starting material density (phospholipids, etc.), which indicates that the walls of the particles are relatively dense and do not contain encased pores. Measurement techniques are known to those slcilled in the art and include, but are not limited to, gas pycnometry (Helium).

DETAILED DESCRIPTION OF THE INVENTION
A description of preferred embodiments of the invention follows.
This invention concerns an improved particulate composition for delivering a drug to the pulmonary system. In particular, the improvement relates to the ideal design of an aerodynamically light particle for inhalation. Specifically, it has been determined that there is a synergistic interrelationship of key characteristics of spray-dried particles that results in an optimal aerodynamic performance of particles for inhaled tllerapeutic aerosols. This synergy promotes finely crumpled yet structurally-robust particles of low tap density (<0.4 g/cm) and relatively large particle geometric size (>5 m) that require less energy to effectively aerosolize than thicker-walled particles of similar size and mass density. Preferably, this design promotes structurally-robust particles of ultra-low tap density (<0.1 g/cm3) and relatively large particle size (>10 m). Preferred particles are hollow, extremely thin-walled particles comprising drugs and, optionally, excipients. Further, the particles of the invention relative to particles of alternative morphologies (i.e., non-hollow particles), require less energy to produce. By reducing particle wall thickness to around 1% of the particle spherical envelope diameter, it is possible to achieve large drug-surface-transport area without necessarily creating the large particle-particle contact area that miderlies handling drawbacks normally associated with nanoparticle drug delivery systems.
It was the discovery of the synergy of the interrelationships of key characteristics that led to iinproved methods for producing and selecting for particles with superior dispersibility. For example, the focus on key characteristics has led to innovations such as on-line sizing in which a "real-time" feedback loop is possible which can reduce waste and optimize the process for making such superior particles.
(See U.S. Patent Application Serial No. 10/101,563 with the title "Method and Apparatus for Producing Dry Particles" filed March 20, 2002, under the Attorney Docket No. 00166.0115) This is especially important in the production of high cost drugs, for example, proteins. Thus, these improved compositions have improved dispersibility due to homogeneity of the particles.
Accordingly, the invention relates to an improved particulate composition.
The improvement is that when the median aerodynamic diameter, median geometric diameter and tap density of two different contiguous shell-based particulate compositions of the same formulation are kept equal, there exists a synergistic relationship between the external surface area, wall thickness, and skeletal density that leads to preferred Fine Particle Fraction (FPF) and dispersibility/flowability as measured by RODOS, RODOS/IHA, or botli. This synergistic relationship results in superior particles which exhibit better dispersibility with less variability over a wide range of entrainment conditions thereby improving the delivery of the particulate composition.
It is known in the art that spray drying a particle formulation under different "operating" conditions can result in spray-dried particles with various characteristics.
However, this invention relates to particles whose performance criteria is tightly controlled to ensure appropriate conformance in other related attributes, for example, particle size, dose content uniformity and lung deposition. Therefore, this invention demonstrates that, although two or more spray-dried powders may have the same median aerodynamic dianieter, median geometric diameter and tap density, that altering the spray-drying conditions of one of the spray-dried formulations to optimize the wall thickness and external surface area of the particles results in formulations possessing a larger surface area, and thus roughness, and thinner walls than the other formulations. Applicants fu.rther demonstrate that the formulation that has optimized the synergistic relationship among the particle characteristics enhances the dispersibility and flowrate independence for that formulation.
In one embodiment, Applicants disclose a method for selectively modulating the individual factors within an extremely tight range (e.g., within 5% of the mean for the individual factor) without interfering with the synergistic relationship. The resulting particles are able to achieve flowrate independence leading to enhanced dispersibility by selectively choosing those particles that have a large geometric -~-diameter (i.e., > 5 m), a small aerodynamic diameter (i.e., a low density with respect to geometric diameter), a minimum average wall thickness and a large external surface area.
In one embodiment of the instant invention, particles of larger size and the highly convoluted morphology contribute to make them easily dispersable and stable with respect to aggregation during storage. In this embodiment, the particle morphology contributes to enhanced dispersability and stability by decreasing the area of contact between particle. The surface contact is minimized by presence of numerous folds and convolutions. The radially-exposed surface is thus reduced as the particle surface is dominated by crevices which cannot interact chemically during contact with other particles. Particles with diameters of <5 m are prone to aggregation, with this tendency increasing as diameter decreases.
In one embodiment, the particles can be fabricated with a rough surface texture to reduce particle aggregation and improve flowability of the powder.
The spray-dried particles have iinproved aerosolization properties. The spray-dried particle can be fabricated with features which enhance aerosolization via dry powder inhaler devices, and lead to lower deposition in the mouth, throat and inhaler device.

As used herein, the term "surface area factor" (a) refers to the ratio of the external and internal surface area of a shell-based particle or particle formulation to the theoretical surface area of a solid spherical particle or particle formulation with the same spherical envelope diameter and tap density. To calculate the surface area factor of a particle, let S = the surface area of a particle of arbitrary shape so that a is defined as:
a = S/(7tDe') where De = the spherical envelope diameter of the particle. For example, if the particle is a solid sphere, where the wall thickness (h) = D~2, S=TcDe2, resulting in a = 1. However, if the particle is a hollow sphere with a wall thickness approaching zero (0), then S = 2TDe2, resulting in a = 2. The invention relates to producing hollow spheres with thin walls (yet having sufficient rigidity to prevent disintegration of the wall) that collapse to form cruxnpled particles, thereby increasing the surface area factor to values greater than 2.

Thus, the invention therefore involves aerodynamically light particles, with improved dispersibilty, wherein the improvement results by collapsing hollow particles with surface area factor between 1 and 2(1<0< 2), to form collapsed particles with surface area factor greater than 2(a>2), ideally greater than 3, and perhaps most ideally greater than 5. The validation of this invention is our finding that drug particles with 1<a<2 aerosolize less well than particles with a>2, a11 other things being equal.
The increased surface areas of the particle distributions disclosed herein can also be described via estimates of particle ragosity. As defined herein, particle rugosity (R) is the ratio of the ratio of the external surface area of a shell-based particle or particle formulation to the theoretical surface area of a solid spherical particle or particle formulation with the same spherical envelope diameter and tap density. Thus, as described above, for shell-based particle forrhulations with wall thicknesses significantly less than particle spherical envelope diameters, particle ragosity will be approximately equal to one-half of the surface area factor (i.e., R
0.5Q).
In another embodiment of the invention the particles can include a surfactant.
As used herein, the term "surfactant" refers to any agent which preferentially adsorbs to an interface between two immiscible phases, such as the interface between water and an organic polymer solution, a water/air interface or organic solvent/air interface. Surfactants generally possess a hydrophilic moiety and a lipophilic moiety, such that, upon absorbing to microparticles, they tend to present moieties to the external environment that do not attract similarly-coated particles, thus reducing particle aggregation. Surfactants may also promote absorption of a therapeutic or diagnostic agent and increase bioavailability of the agent.
Suitable surfactants which can be employed in fabricating the particles of the invention include but are not limited to hexadecanol; fatty alcohols such as polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; a surface active fatty acid, such as palmitic acid or oleic acid; glycocholate; surfactin; a poloxamer; a sorbitan fatty acid ester such as sorbitan trioleate (Span 85); Tween 801and tyloxapol *

* Trademark Methods of preparing and administering particles including surfactants, and in particular phospholipids, are disclosed in U.S. Reissue Patent No. RE
37,053 to Hanes et al. (formerlyU.S. Patent No 5,855,913, issued on January 5, 1999) and in U.S. Patent No. 5,985,309, issued on November 16,1999 to Edwards et al.

In a fizrther embodiment, the particles can also include other excipients such as, for example buffer salts, dextran, polysaccharides, lactose, trehalose, cyclodextrins, proteins, polycationic complexing agents, peptides, polypeptides, fatty acids, fatty acid esters, inorganic compounds, phosphates, lipids, sphingofipids, cholesterol, surfactants, polyaminoacids, polysaccharides, proteins, salts, gelatins, polyvinylpyrridolone and others also can be employed.
In another embodiment, the particles of the invention can include one or more phospholipids. Phospholipids suitable for delivery to a human subject are preferred. Specific examples of phospholipids include but are not limited to phosphatidylcholines dipalmitoyl phosphatidylcholine (DPPC), dipalmitoyl phosphatidylethanolamine (DPPE), distearoyl phosphatidylcholine (DSPC), dipalmitoyl phosphatidyl glycerol (DPPG) or any combination thereof.
The phospholipids or combinations thereof and methods of preparing particles having desired release properties are described in U.S. Patent Application Publication 20020052310 entitled "Particles for Inhalation Having Sustained Release Properties", filed on December 29, 2000 and in U.S. Patent 7,048,908.

The phospholipids can be present in the particles in an amount ranging from about 1 to about 99 weight %. Preferably, they can be present in the particles in an amount ranging from about 10 to about 80 weight %.
In one embodiment, the particles of the invention have a tap density less than about 0.4 g/cm'. Particles which have a tap density of less than about 0.4 g/cm3 are referred herein as "aerodynamically light particles". More preferred are particles having a tap density less than about 0.3 g/cm3. Even more preferred are particles having a tap density less than about 0.2 g/cm3. Preferably, the particles have a tap density less than about 0.1 g/cm3. Tap density can be determined using the method of USP Bulk Density and Tapped Density, United States Pharmacopeia convention, Rockville, MD, 10th Supplement, 4950-4951, 1999. Instruments for measuring tap density, known to those skilled in the art, include but are not limited to the Dual Platform Microprocessor Controlled Tap Density Tester (Vankel, NC) or a GeoPyc instrument (Micrometrics Instrument Corp., Norcross, GA 30093). Tap density is a standard measure of the envelope mass density. The envelope mass density of an isotropic particle is defined as the mass of the particle divided by the minimum spherical envelope volume within which it can be enclosed. Features which can contribute to low tap density include irregular surface texture and porous structure.

Aerodynamically light particles have a preferred size, e.g., a volume median geometric diameter (VMGD) greater than about 5 microns ( m). In one embodiment, the VMGD is from greater than about 5 m to about 30 m. In another embodiment of the invention, the particles have a VMGD ranging from about 10 m to about 30 m. In a preferred embodiment, the particles have a VMGD greater than about 5 m. Even more preferred are particles having a VMGD
greater than about 8 m. Most preferred are particles having a VMGD greater than about 10 m. In other embodiments, the particles have a median diameter, mass median diameter (1VIlVID), a mass median envelope diameter (MMED) or a mass median geometric diameter (MMGD) greater than about 5 m, for example from greater than about 5 m and about 30 m.
The diameter of the spray-dried particles, for example, the VMGD, can be measured using a laser diffraction instrument (for example Helos, manufactured by Sympatec, Princeton, NJ). Other instruxnents for measuring particle diameter are well know in the art. The diaineter of particles in a sample will range depending upon factors such as particle coinposition and methods of synthesis. The distribution of size of particles in a sample can be selected to permit optimal deposition to targeted sites within the respiratory tract.

Aerodynamically light particles preferably have "mass median aerodynamic diameter" (MMAD), also referred to herein as "aerodynamic diameter", between about 1 m and about 5 m. In another embodiment of the invention, the MMAD is between about 1 m and about 3 m. In a finther embodiment, the MMAD is between about 3 m and about 5 m.
Other suitable particles which can be adapted for use in oral delivery as described herein, said particles being described in U.S. Patent Application Publication 20030129250.

The dosage to be administered to the mammal, such as a human, will contain a therapeutically effective amount of a compound described herein.
As used herein, the term "therapeutically effective amount" means the amount needed to achieve the desired therapeutic or diagnostic effect or efficacy when administered to the respiratory tract of a subject in need of treatment, prophylaxis or diagnosis. The actual effective amounts of drug can vary according to the biological activity of the particular compound employed; specific drug or combination thereof being utilized; the particular composition formulated; the mode of administration; the age, weight, and condition of the patient; the nature and severity of the symptoms or condition being treated; the frequency of treatment; the administration of other therapies; and the effect desired. Dosages for a particular patient can be determined by one of ordinary skill in the art using conventional considerations, (e.g. by means of an appropriate, conventional pharmacological protocol).
In one embodiment of the invention, delivery to the pulmonary system of particles is by the methods described in U.S. Patent 6,858,199 and U.S. Patent Application Publication 20020035993.

As disclosed therein, particles are held, contained, stored or enclosed in a receptacle.
Preferably, the receptacle, e.g. capsule or blister, has a volume of at least about 0.37cm3 and can have a design suitable for use in a dry powder inhaler. Larger receptacles having a volume of at least about 0.48 cm3, 0,67 cm3 or 0.95 cm3 also can be employed.
The methods of the invention also relate to administering to the respiratory tract of a subject, particles andlor compositions comprising the particles of the invention, which can be enclosed in a receptacle. As described herein, in certain embodiments, the invention is drawn to methods of delivering the particles of the invention, while in other embodiments, the invention is drawn to methods of delivering respirable compositions comprising the particles of the invention.
As used herein, the term "receptacle" includes but is not limited to, for example, a capsule, blister, film covered container well, chamber and other suitable means of storing particles, a powder or a respirable composition in an inhalation device known to those skilled in the art.
The invention is also drawn to receptacles which are capsules, for example, capsules designated with a particular capsule size, such as 2, 1, 0, 00 or 000.
Suitable capsules can be obtained, for example, from Shionogi (Rockville, MD).
Blisters can be obtained, for example, from Hueck Foils, (Wall, NJ). Other receptacles and other volumes thereof suitable for use in the instant invention are known to those skilled in the art.
Suitable organic solvents that can be employed include but are not limited to alcohols for example, ethanol, methanol, propanol, isopropanol, butanols, and others. Other organic solvents include but are not limited to perfluorocarbons, dichloromethane, chloroform, ether, ethyl acetate, methyl tert-butyl ether and others.
Suitable spray-drying techniques are described, for example, by K. Masters in "Spray Drying Handbook", John Wiley & Sons, New York, 1984. Generally, during spray-drying, heat from a hot gas such as heated air or nitrogen is used to evaporate the solvent from droplets formed by atomizing a continuous liquid feed.
Other spray-drying techniques are well known to those skilled in the art. In a preferred embodiment, a rotary atomizer is employed. Examples of suitable spray driers using rotary atomization include the Mobile Minor spray drier, manufactured by Niro, Denmark. The hot gas can be, for example, air, nitrogen or argon.
Methods and apparatus suitable for forming particles of the present invention are described in U.S. Patent 6,848,197 and in U.S. Patent 6,956,021.

Particles of the invention are suitable for delivery to the pulmonary system.
Preferably, particles administered to the respiratory tract travel through the upper airways (oropharynx and larynx), the lower airways which include the trachea followed by bifurcations into the bronchi and bronchioli and through the terminal bronchioli which in turn divide into respiratory bronchioli leading then to the ultimate respiratory zone, the alveoli or the deep lung. In a preferred embodiment of the invention, most of the mass of particles deposits in the deep lung or alveoli.
"Flowability" refers to a powder characteristic that affects the ease of processing. For a material to be considered to be suitably flowable, it must be amenable to processing in automated equipment (such as capsule fillers or tablet making machines) using industry standard techniques. Flowability is measured using a number of techniques referred to as powder rheometric methods such as shear cell methods and dynamic angles of repose.
"Wettability" and 'hydroscopicit}', can be used interchangably herein, and is a property that affects the interaction of the powder in water. Wettability is a function of surface properties such as surface energy (surface tension) and morphology. This property can be measured using instruments such as dynamic vapor sorption or BET analyzers. Suitable units include water % weight gain.
Powder dispersibility indicators can be obtained via geometric and aerodynamic analytical methods. Geometric size was obtained via laser diffraction (Sympatec RODOS system), with measurements taken at different dispersion pressures used as an indicator of powder dispersibility (e.g, dispersion pressures ranging from 0.25 to 4 bar). The RODOS system can also be used in conjunction with an inhaler attachment system to measure particle size as a function of flowrate (30 - 90 L/min) through an inhaler, providing another indicator of powder dispersibility. Aerodynamic size distributions of the particles can be obtained via an Aerosizer system utilizing an Aerodisperser (API, Amherst, MA).

In a preferred embodiment, the ratio of the sizes obtained at low (0.25 bar) and high (2.0 bar) dispersion pressures (0.25/2 ratio) can be used as an indicator of dispersibility. For example, if a dry powder particle formulation has a 0.25/2 ratio of 3, then the size of the particles measured at low dispersion pressures is three times the size of the particles measured at high dispersion pressures, indicating high levels of particle aggregation at low dispersion pressures. In contrast, if a dry powder particle formulation has a 0.25/2 ratio close to 1, then the size of the particles measured at low dispersion pressures is almost the same as the size of the particles measured at high dispersion pressures, indicating low levels of particle aggregation at low dispersion pressures and flowrate independence.

Similarily, an inhaler to be tested can be attached to the RODOS apparatus (RODOS/IHA) to simulate the conditions under which a powder is emitted from the inhaler. The ratio of the sizes of the powder emitted from an inhaler at low (30 L/min) and high (90 L/min) flowrates (30/90 ratio) can be used as an indicator of dispersibility under clinically relevant conditions. For example, if a dry powder particle formulation has a 30/90 ratio of 3, then the geometric size of the particles measured at low flowrates is three times the size of the particles measured at high flowrates, indicating high levels of particle aggregation at low flowrates. In contrast, if a dry powder particle formulation has a 30/90 ratio close to 1, then the geometric size of the particles measured at low flowrates is almost the same as the size of the particles measured at high flowrates, indicating low levels of particle aggregation at low flowrates, and, thus, enhanced dispersibility and flowrate independence for these particles.

In a prefered embodiment, the invention relates to a method of producing and selecting for particles having a 0.25/2 RODOS ratio that is the same as/similar to the RODOS/IHA 30/90 ratio. The 0.25/2 ratio provides an indication of powder dispersibility under laboratory conditions, whereas the RODOS/IHA 30/90 ratio provides an indication of powder dispersibility under clinical/therapeutic conditions.
Thus, by selecting for particles that have a high correlation between these respective ratios one is able to identify compositions with enhanced dispersibility properties.

In a further einbodiment, Applicants disclose the increased dispersibility of dry powder particle formulations possessing crumpled morphologies over spherical morphology powder formulations with comparable primary particle geometric and aerodynamic sizes. The critical differences between the particle formulations are based on their morphologies, with the crumpled particles possessing larger surface areas and thinner walls than the spherical particles (these differences in surface areas and wall thicknesses are confirmed in the examples below).

EXEMPLIFICATION
Example 1. Production of particles with identical compositions and differing morphologies (spherical vs. crumpled paper).

Forinulations consisting of 60:20:20 wt:wt dipalmitoylphosphatidylcholine (DPPC, Avanti Polar Lipids, Alabaster, AL):bovine serum albumin (BSA, Sigma Chemical Co., St. Louis, MO):lactose (Spectrum Chemical Co., ) were spray-dried in the following manner.

i. Production of particles with spherical morphologies. A Niro Mobile Minor Spray Dryer (Niro Inc., Columbus, MD) equipped with a four vein (V4) rotary atomizer was utilized for powder production. Ethanol:water (70:30 vol:vol) solutions of 4.0 g/l concentrations were utilized for excipient solubilization. For a typical 1 liter batch size, 600 mg DPPC was added to 700 ml of ethanol, and 200 mg of BSA and 200 mg of lactose were added to 300 ml of water (pH adjusted to 8.1 via addition of 1.0 N NaOH after addition of the excipients). The spray drying conditions were as follows: 120 C inlet temperature, 52,000 RPM atomizer spin rate, 70 ml/min solution feed rate, 108 m3/hr drying gas flow rate (Nitrogen).
These conditions resulted in outlet temperatures in the range of 53 - 55 C.
Utilizing a cyclone for powder collection, typical run yields were approximately 40%.

ii. Production of particles with crurnpled paper mor,phologies. A Niro Mobile Minor Spray Dryer (Niro Inc., Columbus, MD) equipped with a twenty-four vein (V24) rotary atomizer was utilized for powder production. Ethanol:water (85:15 vol:vol) solutions of 1.0 g/l concentrations were utilized for excipient solubilization. For a typical 1 liter batch size, 600 mg DPPC was added to 850 ml of ethanol, and 200 mg of BSA and 200 mg of lactose were added to 150 ml of water (pH adjusted to 8.1 via addition of 1.0 N NaOH after addition of the excipients).

The spray drying conditions were as follows: 100 C inlet temperature, 18,000 RPM
atomizer spin rate, 52 ml/min solution feed rate, 100 m3/hr drying gas flow rate (Nitrogen). These conditions resulted in outlet temperatures in the range of C. Utilizing a cyclone for powder collection, typical run yields were approximately 40%.

Example 2 Powder geometric and aerodynamic property characterization.
Powders produced via methods i and ii from Example 1 above were characterized for their geometric and aerodynamic properties. Powder dispersibility indicators (described below) were also obtained via geometric and aerodynamic analytical methods. Geometric size was obtained via laser diffraction (Sympatec RODOS system), with measurements taken at different dispersion pressures used as an indicator of powder dispersibility (experiments were conducted at dispersion pressures ranging from 0.25 to 4 bar. The RODOS system was also used in conjunction with an inhaler attachment system to measure particle size as a function of flowrate (30 - 901/min) through an inhaler, providing another indicator of powder dispersibility. Aerodynamic size distributions of the particles were obtained via an Aerosizer system utilizing an Aerodisperser (API, A.mherst, MA). The results of the geometric, aerodynamic and dispersibility characterization measurements (all data is given in microns) are displayed in Table 1.

Table 1 RODOS Size Measurements ODOS - Inhaler Attachment Aerosizer Powder 0.25 0.5 1 2 4 0.25/2 30 60 90 30/90 Type bar bar bar bar bar ratio 1/min Umin Umin ratio MIVIAD
i. Spherical 24.6 17.7 15.2 12.3 8.57 2.0 23.5 16.1 12.1 1.94 3.20 ii. Crumpled 10.6 10.3 9.91 9.50 8.80 1.12 10.1 9.90 9.65 1.05 3.14 The results shown in Table 1 clearly demonstrate the increased dispersibility of the powder formulations possessing crumpled paper morphologies over spherical morphology powder formulations with comparable primary particle geometric and aerodynamic sizes. Using the RODOS results obtained with a dispersion pressure of 4 bar, the spherical (i) and crumpled paper (ii) particle formulations appear to have similar dispersed particle sizes (8.57 microns for i vs 8.80 microns for ii).
Additionally, the spherical (i) and crumpled paper (ii) particle formulations appear to have comparable aerodynamic diameters as measured via the Aerosizer (3.20 microns for i vs. 3.14 microns for ii), which also indicates that the particle formulations have comparable particle densities. Estimations of particle densities based on the measured RODOS geometric sizes at 4 bar and the MMADs are 0.14 g/cm3 for formulation i and 0.13 g/cm3 for formulation ii. Thus, the main differences between particle formulations i and ii are based on their morphologies, with the formulation ii particles possessing larger surface areas and roughness and thinner walls than the spherical formulation i particles (these differences in surface areas and wall thicknesses are confirmed in the examples below).

As evidenced by the results shown in Table 1, the crumpled paper particle formulation is significantly more dispersible than the spherical paper particle formulation. For example, the ratio of the size obtained via the RODOS system is highly dependent on the dispersion pressure for the formulation i (spherical) particles, with particle aggregation evident at low dispersion pressures. As shown in Table 1, the ratio of the sizes obtained at low (0.25 bar) and high (2.0 bar) dispersion pressures (0.25/2 ratio) can be used as an indicator of dispersibility. The formulation i (spherical) powder has a 0.25/2 ratio of 2, with the size measured at low dispersion pressures being two times the size measured at high dispersion pressures. Ihi contrast, the 0.25/2 ratio for the formulation ii powder (crumpled) is only 1.12, indicating low levels of particle aggregation at low dispersion pressures.

The RODOS/Inhaler attachment results confirm the enhanced dispersibility of the formulation ii (crumpled) powder as emitted from an inhaler at different flowrates. As shown in Table 1 above, the ratio of measured sizes at flowrates of 30 vs. 901iters per minute is nearly equal to 2 for the formulation i (spherical) powder, whereas the ratio for the formulation ii (crumpled) powder is close to 1, indicating enhanced dispersibility and flow rate independence for the crumpled paper morphology powder.

Example 3 SEM Imaging of Particle Morphology and Wall Thickness SEM microscopy was utilized to both elucidate the differences in morphology between crumpled paper and spherical morphology powder samples and to confirm that the crumpled paper morphology powder samples possessed thinner walls than the spherical morphology samples. SEM images of samples of the unaltered powders are displayed in Figures 1(formulation i) and 2 (formulation ii).
For observation of wall thicknesses, the spherical powders were ground via the use of a 3" diameter cyclone in order to fracture some of the particles to enable imaging of wall cross sections, whereas wall thicknesses were estimated for the crumpled paper morphology powders by observation of tightly folded regions (with the assumption that the wall thickness is approximately 1/2 the width of the tightly folded region). Estimates for the wall thicknesses were approximately 150 to nanometers for the spherical particles and 80 to 120 nanometers for the crumpled paper morphology particles.

Example 4 Powder surface area characterization.

The BET isotherm method (Autosorb System, Quantachrome Instruments, Boynton Beach, FL) was used to determine the external surface areas of representative formulation i (spherical) and ii (crumpled paper morphology) powder samples. Sainples were outgassed for 24 hours at ambient temperature before the isotherms were obtained via a 3 point method utilizing nitrogen gas as the adsorbate.
Specific surface areas obtained via this method were 5.16 m2/gram for the formulation i and 8.10 mz/gram for the formulation ii powder. AFM results supported the assumption that the BET isotherm method provided a measure of external particle surface area, with the surface areas as measured via AFM
being equivalent to those obtained via the BET isotherm method (data not shown). To calculate the surface area factors ((Y) for each formulation, the geometric diameters measured via RODOS at a dispersion pressure of 4 bar and the estimated particle densities were used to calculate the equivalent surface area of a solid (low density) particle via the following equation:

SA(equivalent) = 47c R2 = 3 4;rR3*p R*P

This procedure resulted in estimates of 5.00 m2/gram for the formulation i and 5.24 m2/gram for the formulation ii powders, which resulted in surface area factor (6) estimates of 2.06 for the formulation i and 3.09 m2/gram for the formulation ii powders. Using these results with equation 1 described above resulted in wall thickness estimates of approximately 160 nm for the formulation i and 100 nm for the formulation ii powders. These estimates correspond with the wall thicknesses estimated from the SEM images as described above. Thus, these results confirm the fact that, for powders with a given median geometric size and particle density, decreasing the wall thiclcness results in powders with increased surface areas and reduced cohesiveness.

Example 5 Additional examples of drug-containing crumpled paper morphology powders.

Similar results can be obtained utilizing different excipients than those described above for both blank and drug-containing powders possessing crumpled paper morphologies. Utilizing spray drying methods similar to those described in Example 1 above, the following drug-containing powders possessing crumpled paper morphologies were formulated:

a. 68:20:10:2 DPPC:sodium citrate:calcium chloride:albuterol sulfate b. 58:20:20:2 DPPC:DPPE: lactose: estradiol.

The characterization results are displayed in Table 2.
Table 2 RODOS Size Measurements RODOS - II33A Aerosizer BET
Powder 0.25 bar 0.5 bar 1 bar 2 bar 4 bar 0.25/2 ratio 30 60 90 30/90 NIMAD SA
l/min 1/min 1/min ratio (mz/gram) a 12.3 10.7 9.66 8.62 7.25 1.43 10.7 9.63 9.17 1.17 2.54 10.3 b 11.7 10.5 9.38 8.46 7.37 1.38 10.3 9.2 8.8 1.16 2.92 10.5 Estimated particle densities for powders a and b based on the VMGD measured at bar and the MMAD measured via the Aerosizer are 0.12 g/cm3 for Powder a and 0.16 g/cm3 for Powder b (measured tap densities for Powders a and b were 0.12 and 0.11 g/cm3, in agreement with the estimated particle densities). The procedure described in Example 4 above for determining the surface area factors of the powders resulted in estimates of 6.89 m2/gram for Powder a and 5.09 mz/gram for Powder b, which resulted in surface area factor (a) estimates of 2.99 for Powder a and 4.13 for Powder b. AFM results again supported the assumption that the BET
isotherm method provided a measure of external particle surface area, with the surface areas as measured via AFM being equivalent to those obtained via the BET
isotherm method (data not shown). Using these results with equation 1 described above resulted in wall thickness estimates of approximately 80 nm for both Powders a and b.

Example 6 A placebo powder, comprised of 70/20/10 % by weight DPPC/Sodium Citrate/Calcium Chloride, that was used had the following characteristics: Dg=
6.7um; =0.06 g/cm3; Da=1.6um. The primary aerodynamic particle size characteristics were obtained using time-of-flight (AeroSizer/AeroDisperser) and the geometric particle size characteristics were obtained using laser diffraction (measured using the RODOS dry powder disperser and HELOS laser diffractometer, as described herein) operated at 1 and 2 bar. Emitted aerodynamic particle size characteristics were obtained using Andersen cascade impaction (gravimetric analysis) operated at 28.3 L/min, for a total air volume of 2 L. Geometric particle size characteristics were obtained using laser diffraction (RODOS/HELOS, Sympatec, NJ) with inhaler attachment operated at 60 L/min.

Example 7 Highly dispersing powder can efficiently emit and penetrate into the lungs from a range of breatll-activated dry powder inhalers (DPIs). A spray-dried powder was prepared coinprised of sodium citrate, DPPC, calcium chloride buffer and a trace amount of a rhodamine fluorescent label. The powder possessed a median aerodynamic diameter of 2.1 m (measured by the AeroDisperser and Aerosizer) and a geometric diameter of 11.0 m (measuied using the RODOS dry powder disperser and HELOS laser diffractometer, as described herein) and displayed excellent deaggregation properties.

milligrams of the powder were placed in the capsules using a semi-automated capsule filling device in the following inhalers: a breath-activated inhaler under development by Applicants (AIR Inhaler), the Spinhaler (Fisons, Loughborough, U.K.), Rotahaler (Glaxo-Wellcome, RTP, NC), F1owCaps (Hovione, Loures, Portugal), Inhalator' (Boehringer-Ingelheim, Germany), and the Aerolizer (Novartis, Switzerland). The Diskhaler (Glaxo-Welicome, RTP, NC), was also tested for which 3 mg of the powder was machine-filled into the blister packs. Applicants connected each inhaler to a collapsed Andersen cascade impactor (consisting of stage 0 and the filter stage,) and extracted air at 60 L/minutes for 2 seconds after actuating the device. The fine particle fraction less than stage 0, having a 4.0 m cut-off, was determined using fluorescent spectroscopy.
In this study, it was found that in each case, approximately 50% or more of the emitted dose displayed a median aerodynamic diameter (Da) less than 4 m in size, indicating that the powder would efficiently enter the lungs of a human subject at a physiological breath rate, despite the simplicity of these breath-activated devices.It was also that large percentages of a nominal dose at low energy were emitted from not only single dose, breath-actuated inhalers but also from a range of breath-actuated dry powder inhalers (DPIs).

Example 8 Nano-thin particles (i.e. hollow particles with wall thickness around 100 nm) were formed by spray drying ethanol/water cosolvent soltuions of drug and pharmaceutical excipients at inlet temperatures and drying rates that promoted the formation of a thin, dry shell that could collapse to varying degrees depending on the drying conditions. This process proved robust, permitting the formation of nano-thin particles with drugs including insulin, albeterol sulfate, estradiol, human growth hormone, and immunoglobulin, and excipients including lipids, sugars, and amino acids.

Two types of nano-thin particles were produced to test the hypothesis that thin-walled particles aerosolize more easily than thicker-walled particles of similar size and mass density. Powders A and B were designed of dextrin and dipalmitoyl phosphatidyl choline (DPPC) to contain particles possessing median geometric diameter of roughly 10 m and tap density of approximately 0.08 g/cm3. Powder A
revealed a hollow sphere morphology and powder B a crumpled shell morphology.
These morphological differences were related uniquely to the characteristic particle wall thickness h:

h N dp (1) ops where ps is the skeletal mass density of the particle, and a the mean particle surface area per surface area of a nonporous sphere of equivalent spherical envelope diameter, d. Hence, according to the equation, particle wall thickness (h) dictates particle surface area (6), or surface morphology, for hollow-particle powders of constant mass density (p) and size (d). ps was measured by pynonometry (ps =
1.2 g/cm3) and 6 by atomic force microscopy (AFM) (6A = 2.6; 6B = 5.0), leading to particle wall thickness estimates of h=200 nm for the spherical particle A and h=50 nm for the crumpled particle B. These estimates were confirmed visually by transmission electron microscope (TEM) images, indirectly verifying the particle structure assumed as a result of the above equation.

Powders (A) and (B) were placed inside capsules of a Spinhaler dry-powder inhaler (DPI) and actuated the inhaler into a multi-stage liquid impinger (MSLI) to evaluate the aerosolization efficiency of both powders. The MSLI
simulates aerosol flight and deposition in the human lungs, with particles of an aerosol depositing on liquid-coated, parallel, stacked plates according to their aerodynamic size. Particles determined by the MSLI to possess aerodynamic size below about 5 m, at a physiological flow rate (e.g. 60 L/min), are assumed sufficiently small to pass through the mouth and throat, and enter the lungs, during a human inhalation. The fraction of the original powder mass in the inhaler with aerodynamic size below 5 um was termed the fine-particle fraction. This fraction was 40% for powder A, and 70% for powder B, using the MSLI with an inhalation flow rate of 60 L/min.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

Claims

1. A particulate composition for delivery to the pulmonary system comprising particles having a tap density of less than 0.4 g/cm3 and a median geometric diameter greater than about 5 µm, and an external surface area greater than about 5 m2/g and a skeletal density of at least about 1 g/cm3.

2. The particulate composition of Claim 1 further comprising a drug.

3. The particulate composition of Claim 2 further comprising a pharmaceutical excipient.

4. The particulate composition of Claim 1 further comprising a dispersibility ratio of median geometric diameters of between about 1.0 to about 1.5 as measured by laser diffraction.

5. A particulate composition for delivery of a drug to the pulmonary system comprising particles having a tap density of less than 0.4 g/cm3 and a geometric diameter greater than about 5 µm, said particles having a continuous collapsed hollow sphere wall, said wall having a wall thickness less than about 150 nanometers and an external surface area of at least about 5 m2/g.

6. The particulate composition of Claim 5, wherein at least 70% of the particles have a fine particle fraction of less than about 5.6 µm.

7. The particulate composition of Claim 1 having a surface area factor of greater than 2.

8. The particulate composition of Claim 1 having a surface area factor of greater than 3.

9. The particulate composition of Claim 1, wherein the particles have a continuous collapsed hollow sphere wall.

10. The particulate composition of Claim 1, wherein the external surface area is greater than about 8 m2/g.

11. The particulate composition of Claim 1, wherein the external surface area is greater than about 10 m2/g.

12. The particulate composition of Claim 1, wherein the tap density is less than 0.1 g/cm3.

13. The particulate composition of Claim 6 having a surface area factor of greater than 2.

14. The particulate composition of Claim 6 having a surface area factor of greater than 3.

15. The particulate composition of Claim 6, wherein the external surface area is greater than about 8 m2/g.

16. The particulate composition of Claim 6, wherein the external surface area is greater than about 10 m2/g.

17. The particulate composition of Claim 6, wherein the tap density is less than 0.1 g/cm3.

18. A particulate composition for delivery of a drug to the pulmonary system comprising particles having:
(a) a tap density of less than 0.1 g/cm3, (b) a geometric diameter greater than about 5 µm;
(c) an external surface area of at least about 8 m2/g;
(d) a surface area parameter of greater than 3;
(e) at least 70% of the particles have a fine particle fraction of less than about 5.6 µm; and (f) a continuous collapsed hollow sphere wall, said wall having a wall thickness less than about 150 nanometers.

19. A particulate composition for delivery to the pulmonary system comprising particles having a tap density of less than 0.4 g/cm3 and a median geometric diameter greater than about 5 µm, and an external surface area greater than about 5 m2/g wherein the particles have a continuous collapsed hollow sphere wall.

20. The particulate composition of Claim 19 further comprising a drug.

21. The particulate composition of Claim 20 further comprising a pharmaceutical excipient.

22. The particulate composition of Claim 21 further comprising a dispersibility ratio of median geometric diameters of between about 1.0 to about 1.5 as measured by laser diffraction.

23. The particulate composition of Claim 22 having a surface area factor of greater than 2.

24. The particulate composition of Claim 22 having a surface area factor of greater than 3.

25. The particulate composition of Claim 22, wherein the external surface area is greater than about 8 m2/g.

26. The particulate composition of Claim 22, wherein the external surface area is greater than about 10 m2/g.

27. The particulate composition of Claim 22, wherein the tap density is less than 0.1 g/cm3.